Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics

LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway

(2021) Xiaoming Wang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1

(2021) Adam D. Cotton et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

HIF1A-AS2 Promotes the Proliferation and Metastasis of Gastric Cancer Cells Through miR-429/PD-L1 Axis

(2021) Linsong Mu et al.   DIGESTIVE DISEASES AND SCIENCES

Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1

(2021) Yanhong Zhang et al.   Molecular Oncology

Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens

(2021) Efthymia Papalexi et al.   NATURE GENETICS

HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer

(2021) Yanbin Liu et al.   ONCOGENE

Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor

(2021) Joseph E. Grossman et al.   ONCOGENE

Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy

(2021) Fengling Wang et al.   NEOPLASIA

Casp8 Acts Through A20 to Inhibit PD‐L1 Expression: The Mechanism and Its Implication in Immunotherapy

(2021) Jiahuan Zou et al.   CANCER SCIENCE

GSK-3: a multifaceted player in acute leukemias

(2021) Alberto M. Martelli et al.   LEUKEMIA

Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade

(2021) Xiaoming Dai et al.   MOLECULAR CELL

Molecular Targeted Agent and Immune Checkpoint Inhibitor Co-Loaded Thermosensitive Hydrogel for Synergistic Therapy of Rectal Cancer

(2021) Huaiyu Zhang et al.   Frontiers in Pharmacology

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

(2021) Wei Sun et al.   Frontiers in Oncology

In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC)

(2021) Yubo Wang et al.   BIOORGANIC CHEMISTRY

M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma

(2021) Xinyao Qiu et al.   CANCER RESEARCH

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy

(2021) Kazuhiro Koikawa et al.   CELL

HGF/c‐MET pathway contributes to cisplatin‐mediated PD‐L1 expression in hepatocellular carcinoma

(2021) Zhan‐Sheng Zhang et al.   CELL BIOLOGY INTERNATIONAL

ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer

(2021) Zhe Tang et al.   CLINICAL CANCER RESEARCH

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy

(2021) Jannie Borst et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Membrane-Associated RING-CH 8 Functions as a Novel PD-L1 E3 Ligase to Mediate PD-L1 Degradation Induced by EGFR Inhibitors

(2021) Guoqing Qian et al.   MOLECULAR CANCER RESEARCH

Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy

(2021) Hongbo Zhang et al.   MOLECULES

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

(2021) Pottayil G. Sasikumar et al.   Communications Biology

Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells

(2020) Haifang Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Pembrolizumab for Early Triple-Negative Breast Cancer

(2020) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decitabine Augments Chemotherapy-Induced PD-L1 Upregulation for PD-L1 Blockade in Colorectal Cancer

(2020) Kevin Chih-Yang Huang et al.   Cancers

ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis

(2020) Hong Liu et al.   CANCER CELL

Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells

(2020) Yihe Yan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Regulation of sister chromatid cohesion by nuclear PD-L1

(2020) Jia Yu et al.   CELL RESEARCH

Epigenetically silenced PD-L1 confers drug resistance to anti-PD1 therapy in gastric cardia adenocarcinoma

(2020) Tianyu Zhu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment.

(2020) Anthony B. El-Khoueiry et al.   JOURNAL OF CLINICAL ONCOLOGY

Verteporfin Inhibits PD-L1 through Autophagy and the STAT1–IRF1–TRIM28 Signaling Axis, Exerting Antitumor Efficacy

(2020) Jiyong Liang et al.   Cancer Immunology Research

MicroRNA‐155‐5p suppresses PD‐L1 expression in lung adenocarcinoma

(2020) Jiansheng Huang et al.   FEBS Open Bio

Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer

(2020) Yehui Shi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Angiotensin II contributes to intratumoral immunosuppression via induction of PD-L1 expression in non-small cell lung carcinoma

(2020) Kaiyong Yang et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

ALKBH5 regulates anti–PD-1 therapy response by modulating lactate and suppressive immune cell accumulation in tumor microenvironment

(2020) Na Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Lnc-OC1 Induced Cell Apoptosis and Decreased Cell Viability by Releasing miR-34a and Inhibiting PD-L1 in Endometrial Carcinoma

(2020) Yun Liu et al.   Reproductive Sciences

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective

(2020) Libin Guo et al.   Frontiers in Immunology

RNA N6-methyladenosine demethylase FTO regulates PD-L1 expression in colon cancer cells

(2020) Nobuhiro Tsuruta et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

eEF2K enhances expression of PD-L1 by promoting the translation of its mRNA

(2020) Yu Wu et al.   BIOCHEMICAL JOURNAL

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy

(2020) Yang Gao et al.   NATURE CELL BIOLOGY

PD-L1-mediated gasdermin C expression switches apoptosis to pyroptosis in cancer cells and facilitates tumour necrosis

(2020) Junwei Hou et al.   NATURE CELL BIOLOGY

LncRNA SNHG15 Contributes to Immuno-Escape of Gastric Cancer Through Targeting miR141/PD-L1

(2020) Shengchun Dang et al.   OncoTargets and Therapy

Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy

(2020) Leilei Ai et al.   Drug Design Development and Therapy

Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma

(2020) Lilan Yi et al.   Molecular Therapy-Nucleic Acids

The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment

(2020) Katie Hudson et al.   Frontiers in Immunology

Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity

(2020) Vivian Weiwen Xue et al.   Cancers

The therapeutic significance of the novel photodynamic material TPE-IQ-2O in tumors

(2020) Liyu Wang et al.   Aging-US

Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1

(2020) Dan Zhu et al.   CELL DEATH AND DIFFERENTIATION

NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion

(2020) Hongwei Lv et al.   Cell Metabolism

Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma

(2020) Fei Fan et al.   Hepatology International

FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis

(2020) Feng Zhu et al.   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression

(2020) Binu Sasi et al.   LEUKEMIA

The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD‐L1

(2020) Hui Li et al.   Advanced Science

Regulation of PD-L1 expression in K-ras-driven cancers through ROS-mediated FGFR1 signaling

(2020) Christophe Glorieux et al.   Redox Biology

PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3

(2020) Daozhi Xu et al.   Frontiers in Cell and Developmental Biology

Translation control of the immune checkpoint in cancer and its therapeutic targeting

(2019) Yichen Xu et al.   NATURE MEDICINE

MiR-873/PD-L1 axis regulates the stemness of breast cancer cells

(2019) Lanlan Gao et al.   EBioMedicine

WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer

(2019) Lorenzo Castagnoli et al.   ONCOGENE

HDAC3 inhibition up-regulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy

(2019) Siyu Deng et al.   MOLECULAR CANCER THERAPEUTICS

LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195

(2019) Qing-Ming Wang et al.   LIFE SCIENCES

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

(2019) Bo Gong et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity

(2019) Abdul Abbas et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1

(2019) Hui Li et al.   GASTROENTEROLOGY

Upregulation of PD-L1 via HMGB1-activated IRF3 and NF-kB contributes to UV radiation-induced immune suppression

(2019) Wei Wang et al.   CANCER RESEARCH

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

(2019) Han Yao et al.   Nature Biomedical Engineering

Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis

(2019) Yibo Fan et al.   ANNALS OF SURGICAL ONCOLOGY

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory

(2019) Mauro Poggio et al.   CELL

Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway

(2019) Mingjing Shen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Glycolytic Activation of Peritumoral Monocytes Fosters Immune Privilege via PFKFB3-PD-L1 axis in Human Hepatocellular Carcinoma

(2019) Dong-Ping Chen et al.   JOURNAL OF HEPATOLOGY

MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells

(2019) Thijs S Stutvoet et al.   JOURNAL OF PATHOLOGY

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

(2019) Abdullah Al Emran et al.   TRENDS IN IMMUNOLOGY

The Potential for microRNA Therapeutics and Clinical Research

(2019) Johora Hanna et al.   Frontiers in Genetics

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

Long noncoding RNA LINC00473 drives the progression of pancreatic cancer via upregulating programmed death-ligand 1 by sponging microRNA-195-5p

(2019) Wen-Yang Zhou et al.   JOURNAL OF CELLULAR PHYSIOLOGY

IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion

(2019) Li-Chuan Chan et al.   JOURNAL OF CLINICAL INVESTIGATION

The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy

(2019) Yuan Wei et al.   JOURNAL OF CLINICAL INVESTIGATION

CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not?

(2019) Bogdan Musielak et al.   MOLECULES

MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function

(2019) Hyun Kyung Ahn et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tumor suppressor TET2 promotes cancer immunity and immunotherapy efficacy

(2019) Yan-ping Xu et al.   JOURNAL OF CLINICAL INVESTIGATION

BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts

(2019) Daofu Feng et al.   ONCOGENE

1209PExcellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1

(2019) V Radhakrishnan et al.   ANNALS OF ONCOLOGY

Doxorubicin inhibits PD-L1 expression by enhancing TTP-mediated decay of PD-L1 mRNA in cancer cells

(2019) Dong Jun Kim et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse

(2019) Tadashi ASHIZAWA et al.   BIOMEDICAL RESEARCH-TOKYO

Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

(2019) Huiying Han et al.   CANCER CELL

Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design

(2019) Sen Zou et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

P2.06-07 Phase 1 Study of CA-170: First-in-Class Small Molecule Targeting VISTA/PD-L1 in Patients with Malignant Pleural Mesothelioma

(2019) M. Zauderer et al.   Journal of Thoracic Oncology

EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma

(2019) Gang Xiao et al.   Journal for ImmunoTherapy of Cancer

Proteolytic processing of PD-L1 by ADAM proteases in breast cancer cells

(2019) Yeni Romero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1

(2019) Jing-Ran Sun et al.   CELLULAR & MOLECULAR BIOLOGY LETTERS

KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the β-catenin/STT3 signaling pathway

(2019) Zhiyan Ruan et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer

(2019) Yoshie Kobayashi et al.   SEMINARS IN CANCER BIOLOGY

MiR-142 inhibits cecal ligation and puncture (CLP)-induced inflammation via inhibiting PD-L1 expression in macrophages and improves survival in septic mice

(2018) Jie Zhen et al.   BIOMEDICINE & PHARMACOTHERAPY

Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1

(2018) Bai He et al.   BIOMEDICINE & PHARMACOTHERAPY

Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1

(2018) Chia-Wei Li et al.   CANCER CELL

Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models

(2018) Sai Kiran Sharma et al.   CANCER RESEARCH

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1

(2018) Helena J. Janse van Rensburg et al.   CANCER RESEARCH

Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth

(2018) Yi Yang et al.   CELL RESEARCH

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

(2018) Wei-Bin Xie et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint

(2018) Zhen Tao et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer

(2018) Meixuan Chen et al.   Clinical Breast Cancer

Epstein−Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas

(2018) Eleni Anastasiadou et al.   LEUKEMIA

Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels

(2018) LiJun Xu et al.   Molecular Oncology

Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4–miR-18a pathway in cervical cancer

(2018) Peixin Dong et al.   ONCOGENE

Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway

(2018) Shaojia Wang et al.   ONCOGENE

Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy

(2018) Bo Zhu et al.   ONCOGENE

Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

(2018) Alessandro Prestipino et al.   Science Translational Medicine

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

(2018) Fei Tang et al.   Cell and Bioscience

YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma

(2018) Min Hwan Kim et al.   Cancer Immunology Research

Deubiquitination and stabilization of programmed cell death ligand 1 by ubiquitin-specific peptidase 9, X-linked in oral squamous cell carcinoma

(2018) Wu Jingjing et al.   Cancer Medicine

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles

(2018) Franz L. Ricklefs et al.   Science Advances

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

(2018) Tammy Linlin Song et al.   BLOOD

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response

(2018) Gang Chen et al.   NATURE

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper

(2018) Franziska Roth-Walter et al.   ALLERGY

A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression

(2018) Kathleen M. Mahoney et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model

(2018) Diana Llopiz et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Palmitoylation stabilizes PD-L1 to promote breast tumor growth

(2018) Yi Yang et al.   CELL RESEARCH

DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer

(2018) Jing Li et al.   EXPERIMENTAL CELL RESEARCH

HIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity

(2018) Huanbin Wang et al.   Nature Chemical Biology

Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma

(2018) Michaël Cerezo et al.   NATURE MEDICINE

Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer

(2018) Jayati Chakrabarti et al.   Oncotarget

Tumour-activated neutrophils in gastric cancer foster immune suppression and disease progression through GM-CSF-PD-L1 pathway

(2017) Ting-ting Wang et al.   GUT

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages

(2017) Canhua Jiang et al.   IMMUNOBIOLOGY

Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells

(2017) Xun Wang et al.   IMMUNOLOGY LETTERS

MicroRNA-155 induction via TNF-α and IFN-γ suppresses expression of programmed death ligand-1 (PD-L1) in human primary cells

(2017) Daniel Yee et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC

(2017) L.L. Bu et al.   JOURNAL OF DENTAL RESEARCH

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

(2017) Chunwan Lu et al.   JNCI-Journal of the National Cancer Institute

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

(2017) Steven C. Kao et al.   Journal of Thoracic Oncology

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma

(2017) V Atsaves et al.   LEUKEMIA

Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1

(2017) Christina M. Maher et al.   MOLECULAR CANCER RESEARCH

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators

(2017) Riccardo Mezzadra et al.   NATURE

Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance

(2017) Jinfang Zhang et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells

(2017) Lukasz Skalniak et al.   Oncotarget

PD-1/PD-L1 interaction up-regulates MDR1/P-gp expression in breast cancer cells via PI3K/AKT and MAPK/ERK pathways

(2017) Shengwei Liu et al.   Oncotarget

A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma

(2017) Paolo D'Arrigo et al.   Oncotarget

PD-L1 promoter methylation mediates the resistance response to anti-PD-1 therapy in NSCLC patients with EGFR-TKI resistance

(2017) Yan Zhang et al.   Oncotarget

PD-L1 (CD274) and PD-L2 (PDCD1LG2) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas

(2017) Alina Franzen et al.   Oncotarget

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

(2017) Valentina Audrito et al.   Oncotarget

BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1

(2017) Simon J. Hogg et al.   Cell Reports

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

The MLL1-H3K4me3 Axis-Mediated PD-L1 Expression and Pancreatic Cancer Immune Evasion

(2017) Chunwan Lu et al.   JNCI-Journal of the National Cancer Institute

Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy

(2017) Chunlin Li et al.   Cancer Immunology Research

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

(2017) Jun Zhou et al.   Cancer Immunology Research

Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton

(2017) Henrick Horita et al.   NEOPLASIA

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer

(2016) Julie George et al.   CLINICAL CANCER RESEARCH

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

(2016) Margaretha G.M. Roemer et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

(2016) Seiichi Ikeda et al.   Journal of Thoracic Oncology

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

(2016) S. J. Hogg et al.   MOLECULAR CANCER THERAPEUTICS

Essential role of HDAC6 in the regulation of PD-L1 in melanoma

(2016) M. Lienlaf et al.   Molecular Oncology

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity

(2016) R. D. Dorand et al.   SCIENCE

Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer

(2016) Glen Reid et al.   Epigenomics

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

(2016) Daniel Sanghoon Shin et al.   Cancer Discovery

The tumor suppressor miR-138-5p targets PD-L1 in colorectal cancer

(2016) Lian Zhao et al.   Oncotarget

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression

(2016) Hengrui Zhu et al.   Cell Reports

AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells

(2016) Sherif Abdelhamed et al.   Journal of Cancer

Mycobacteria-responsive sonic hedgehog signaling mediates programmed death-ligand 1- and prostaglandin E2-induced regulatory T cell expansion

(2016) Sahana Holla et al.   Scientific Reports

Blocking of the PD-1/PD-L1 Interaction by aD-Peptide Antagonist for Cancer Immunotherapy

(2015) Hao-Nan Chang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells

(2015) Marianne Boes et al.   CANCER LETTERS

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN  That Induce PD-L1 Expression in Head and Neck Cancer

(2015) F. Concha-Benavente et al.   CANCER RESEARCH

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

N6-methyladenosine Modulates Messenger RNA Translation Efficiency

(2015) Xiao Wang et al.   CELL

Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia

(2015) Xi Wang et al.   CELLULAR SIGNALLING

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

(2015) S. Loi et al.   CLINICAL CANCER RESEARCH

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma

(2015) Siwen Hu-Lieskovan et al.   Science Translational Medicine

IL-27 induces the expression of IDO and PD-L1 in human cancer cells

(2015) Grazia Carbotti et al.   Oncotarget

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy

(2015) Wenfeng Fang et al.   Oncotarget

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma

(2014) David D. W. Twa et al.   BLOOD

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

(2014) Chunxiao Xu et al.   CANCER CELL

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

MicroRNA-513 Regulates B7-H1 Translation and Is Involved in IFN- -Induced B7-H1 Expression in Cholangiocytes

(2014) A.-Y. Gong et al.   JOURNAL OF IMMUNOLOGY

Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation

(2014) Dagmar Quandt et al.   Journal of Translational Medicine

A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells

(2013) I. B. Barsoum et al.   CANCER RESEARCH

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

(2013) H Yang et al.   LEUKEMIA

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition

(2012) X. Jiang et al.   CLINICAL CANCER RESEARCH

Regulation of cytoplasmic mRNA decay

(2012) Daniel R. Schoenberg et al.   NATURE REVIEWS GENETICS

miR-34 – a microRNA replacement therapy is headed to the clinic

(2012) Andreas G. Bader   Frontiers in Genetics

Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

(2011) X. Frigola et al.   CLINICAL CANCER RESEARCH

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

The miR-15/107 Group of MicroRNA Genes: Evolutionary Biology, Cellular Functions, and Roles in Human Diseases

(2010) John R. Finnerty et al.   JOURNAL OF MOLECULAR BIOLOGY

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination

(2009) V. Pulko et al.   JOURNAL OF IMMUNOLOGY

Upstream open reading frames cause widespread reduction of protein expression and are polymorphic among humans

(2009) S. E. Calvo et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells

(2008) Yigang Qian et al.   CANCER INVESTIGATION

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA